Workshop: Recent Advances in Oral Peptide Delivery – From Molecule to Market

Sponsored By 

Chair(s)

• 

  Andy Lewis, BPharm (Hons) PhD (he/him/his)

  Chief Scientific Officer
  Quotient Sciences
  Nottingham, United Kingdom
• 

  Stephen Buckley, PhD

  Vice President, Drug Product Research
  Novo Nordisk
  Maaloev, Denmark
• 

  David Brayden, PhD (he/him/his)

  Professor of Advanced Drug Delivery
  University College Dublin
  Dublin, Dublin, Ireland

Sponsored by: Bristol Myers Squibb Co., Frontiers Media S.A., Genentech, Inc., Janssen Phamaceutica NV, A Johnson & Johnson Company, Novo Nordisk, Protagonist Theraputics, Quotient Sciences

Systemic delivery of peptides by the oral route is now a reality with multiple products on the market and many more in development. Attendees will learn of the latest advances in oral peptide delivery and its future directions from world leading academics and industry leaders who have successfully taken oral peptide products from preclinical development to translation into the clinic and market launch. Topics covered include fundamental mechanisms, peptide engineering, oral peptide biopharmaceutics, novel drug delivery systems and their clinical development. Insights and learnings will be shared on how to navigate the unique challenges oral peptide programs present and future directions of the field.

Presentations:

• 8:00 AM - 8:30 AM EDT

  Welcome & Introductions
• 8:30 AM - 9:00 AM EDT

  An assessment of the trends in oral peptide administration
  

  Chair and Speaker: David J. Brayden, PhD (he/him/his) – University College Dublin
• 9:00 AM - 9:30 AM EDT

  Characterization of macrocyclic peptide drug interactions with bile salts and biorelevant colloids in the context of oral delivery
  

  Speaker: Tahnee J. Dening, PhD (she/her/hers) – Genentech, Inc.
• 9:30 AM - 10:00 AM EDT

  Overcoming barriers to oral macromolecule delivery: What is coming next
  

  Chair and Speaker: Stephen T. Buckley, PhD – Novo Nordisk
• 10:00 AM - 10:30 AM EDT

  Coffee Break
• 10:30 AM - 11:00 AM EDT

  Applications of PBPK Modelling in Oral Peptide Delivery
  

  Speaker: Ricardo Diaz de Leon Ortega, MS, PhD – Quotient Sciences
• 11:00 AM - 11:30 AM EDT

  Pre-clinical screening of permeation enhancers for oral peptide administration in oral dosage forms: update on GI-ORIS
  

  Speaker: Tom von Erlach, PhD (he/him/his) – Vivtex Corporation
• 11:30 AM - 12:00 PM EDT

  Employing Endogenous Pathways for Efficient Paracellular Uptake of Peptide and Vesicular Transcytosis of Protein Therapeutics
  

  Speaker: Randy Mrsny, PhD (he/him/his) – University of Bath
• 12:00 PM - 12:30 PM EDT

  Oral Peptide Roundtable 1
  

  Chair: David J. Brayden, PhD (he/him/his) – University College Dublin

  Speaker: Andy Lewis, BPharm (Hons) PhD (he/him/his) – Quotient Sciences

  Speaker: Randy Mrsny, PhD (he/him/his) – University of Bath

  Speaker: Neil Mathias, PhD (he/him/his) – Bristol Myers Squibb
• 12:30 PM - 1:30 PM EDT

  Lunch Break
• 1:30 PM - 2:00 PM EDT

  The development of the oral macrocyclic peptide enlicitide (MK-0616), for the treatment of hypercholesterolemia
  

  Speaker: Douglas Johns, PhD, FAHA – Merck Research Laboratories
• 2:00 PM - 2:30 PM EDT

  Enabling Oral Delivery of Peptides through Molecular and Formulation Design
  

  Speaker: Sumit Arora, PhD – Johnson and Johnson Innovative Medicine
• 2:30 PM - 3:00 PM EDT

  An Oral Macrocycle to Access Intracellular RAS Targets in Cancer: The Road to Formulation Design of LUNA18 for Phase I Trials
  

  Speaker: Takamitsu Ueto, PhD (he/him/his) – Chugai Pharmaceutical Co., Ltd
• 3:00 PM - 3:30 PM EDT

  Coffee Break
• 3:30 PM - 4:00 PM EDT

  BIONND™, a Drug Delivery Technology for Efficient Oral Administration of Peptides and Biologics
  

  Speaker: Karsten Lindhardt, PhD MS DBE (he/him/his) – Biograil ApS
• 4:00 PM - 4:30 PM EDT

  Oral Peptide Roundtable 2
  

  Chair: David J. Brayden, PhD (he/him/his) – University College Dublin

  Speaker: Manuel Sanchez-Felix, PhD (he/him/his) – Halozyme

  Speaker: Stephen T. Buckley, PhD – Novo Nordisk

  Speaker: Mo Masjedizadeh, PhD – Protagonist Therapeutics